Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives

ClinicalTrials.gov ID: NCT00508365

Public ClinicalTrials.gov record NCT00508365. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Evaluate the Potential Incidence of Orthostatic Hypotension in Elderly Hypertensive Patients Following Administration of a Combination of COREG CR and Lisinopril

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center, double-blind, randomized, placebo-controlled, 2-session crossover study to evaluate the incidence of orthostatic hypotension in elderly hypertensive subjects following co-administration of carvedilol CR and lisinopril.

Study identification

NCT ID: NCT00508365
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 62 participants

Conditions and interventions

Conditions

Hypertension

Interventions

Drug

Eligibility (public fields only)

Age range: 65 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 25, 2007 (Actual)
Primary completion: Jun 3, 2008 (Actual)
Completion: Jun 3, 2008 (Actual)
Last update posted: Aug 9, 2017

2007 – 2008

United States locations

U.S. sites: 20
U.S. states: 13
U.S. cities: 20

Facility	City	State	ZIP	Site status
GSK Investigational Site	Anniston	Alabama	36207	—
GSK Investigational Site	Glendale	Arizona	85308	—
GSK Investigational Site	Anaheim	California	92801	—
GSK Investigational Site	Beverly Hills	California	90211	—
GSK Investigational Site	Long Beach	California	90806	—
GSK Investigational Site	Coral Gables	Florida	33134	—
GSK Investigational Site	Miami	Florida	33169	—
GSK Investigational Site	Sarasota	Florida	34239	—
GSK Investigational Site	West Palm Beach	Florida	33409	—
GSK Investigational Site	Boise	Idaho	83704	—
GSK Investigational Site	Indianapolis	Indiana	46260	—
GSK Investigational Site	Las Vegas	Nevada	89119	—
GSK Investigational Site	Hackensack	New Jersey	07601	—
GSK Investigational Site	Fargo	North Dakota	58103	—
GSK Investigational Site	Cleveland	Ohio	44122	—
GSK Investigational Site	Oklahoma City	Oklahoma	73132	—
GSK Investigational Site	Portland	Oregon	97239	—
GSK Investigational Site	Austin	Texas	78704	—
GSK Investigational Site	Houston	Texas	77081	—
GSK Investigational Site	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00508365, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 9, 2017 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00508365 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →